MM4I holds three systems. Each is commercialised on its own terms. Integrated, they form one treatment engine with a single endpoint.
Medicines and Machines for Innovation. We enter through oncology, where entering can be justified.
Three systems
MM4I acquires and holds intellectual property arising from publicly funded research, carries the regulatory strategy, and takes each system to market on its own before any of them are joined.
System 01 · held by MM4I
Patient-derived evidence in place of extensive preclinical testing. Protected by the Microorganopits patent family and copyright, acquired from LMU Munich.
System 02 · Oncera
Computational design and ranking of tumour-selective binders, ordered before anything is made.
System 03 · held by MM4I
A continuous, imaging-derived measure of treatment response for early-phase oncology studies.
VITE
Each system runs its own course. Extensive preclinical testing gives way to organoids, algorithmic predictors train on what those produce, and both the methods and the candidates move in silico. CT efficacy joins last, once there is something to measure.
Holding all three means one regulatory argument covers the whole path.
Three technologies, three businesses. Organoids and discovery converge first, CT efficacy joins once there is a response to measure, and from there a single path runs to the endpoint.
The entry point
Individualised medicine asks a patient to accept an approach that, by construction, has not been tested on people like them. We believe advanced solid tumours are where that question can be approached most carefully, and where the variation between patients is a large part of the clinical problem in the first place.
The counterfactual is often weak
In advanced solid cancers, once the standard lines are exhausted, the remaining options can be limited. The case for examining something new is easier to make where the established option has least left to offer.
The framework already exists
Molecular tumour boards, early-phase units and established ethics review already govern individual treatment decisions in oncology. We work inside that framework.
The initial context of use stays deliberately narrow, the clinical and ethical frame is built together with a university-hospital partner, and the path runs through regulatory-science dialogue. None of this is settled, and we would rather work slowly through those questions than around them.
Portfolio
Assets are listed with their identifiers.
Software, model weights, training and evaluation pipelines, datasets and documentation.
Method, validation framework and regulatory strategy. A non-confidential concept summary is available on request.
Takes the discovery system to market under its own name.
Contact
MM4I works with university hospitals, research institutes, funding bodies and industry partners. If your work touches any layer of the stack, we would like to hear from you.
Register
Amtsgericht München